Jim DeMesa, M.D., M.B.A.
Dr. DeMesa has 27 years of executive experience in biotech product development, including clinical and regulatory management and partnering with small and large pharmaceutical, biotech, and medical device companies. He has raised more than $150 million to advance product development into clinical stage, regulatory approval and commercialization. He is the former CEO of two public biotech companies, Migenix Inc. and GenSci Regeneration Sciences, which is now part of Integra LifeSciences (NASD: IART). Dr. DeMesa is a director of two biotech companies: OncoSec Medical (NASD:ONCS), and Induce Biologics. Prior to the CEO positions, he was Vice President of Medical and Regulatory Affairs at Biodynamics International, now part of RTI Surgical (NASD:RTIX), and Vice President of Medical and Regulatory Affairs at Bentley Pharmaceuticals, now part of Teva Pharmaceuticals (NYSE: TEVA), and a practicing physician.
Dr. DeMesa has a B.A. in Chemistry, an M.D., and an M.B.A., all from the University of South Florida.
SCIENTIFIC ADVISORY BOARD MEMBER
Dr. Giovanni Appendino, Ph.D.
Dr. Appendino has studied cannabis and cannabinoids for more than 15 years and is regarded by the global scientific community as one of the worlds thought leaders in cannabinoid research. He was the keynote speaker at the 2014 ICRS Symposium, held in Baveno, Italy. He has been Director of Research and Development in Indena S.p.A. since 2006 and is a Professor of Pharmaceutical Chemistry at the University of Eastern Piedmont (UPO) in Italy. Dr. Appendino has been the local coordinator of three EU research programs, and his research on natural products chemistry focuses primarily on medium-sized cyclic compounds, such as cannabinoids.
He also serves as Editor in Chief of the scientific journal Fitoterapia, and belongs to the publishing advisory board of several journals of the area of Organic Chemistry and Natural Products. Dr. Appendino is the author of more than 250 articles and 10 book chapters, and holds six patents (four of which relate to cannabinoids).
PRE-CLINICAL DRUG DEVELOPMENT
Mari Luz Bellido, M.B.A., Ph.D., Managing Director VivaCell
Dr. Bellido is the Managing Director of VivaCell Biotechnology España SL, a privately held, preclinical-stage pharmaceutical company based in Córdoba, Spain. VivaCell is a worldwide pioneer in the discovery and development of new cannabinoid and cannibigerol derivatives for the treatment of inflammatory and neurodegenerative diseases. She has extensive experience in academic research and pharmaceutical drug discovery and has co-authored numerous peer-reviewed papers and patents. She also has developed expertise in start-up and R&D financing, innovation and project management of cannabinoids for therapeutic use. After joining VivaCell In 2008 as Chief Scientific Officer, Dr. Bellido become a partner in 2012 and was appointed Managing Director of the Company. She participates in all stages of the pre-clinical development from project management to interactions with financing bodies and with the investment community in fund raising.
Dr. Bellido received her Ph.D. in Molecular Biology from the University of Córdoba in Spain, and her M.B.A. from Spain’s ESIC Business and Marketing School.
PRE-CLINICAL DRUG DEVELOPMENT
Prof. Dr. Eduardo Munoz, Ph.D.
Prof. Dr. Eduardo Muñoz is a co-founder of two biotech companies, VivaCell Biotechnology of Spain and Glactone Pharma AB of Sweden, as well as a member of the Strategic Advisory Board at Aphios Corporation in the U.S. A Professor of Immunology in the Department of Cell Biology, Physiology and Immunology of the University of Córdoba (Spain), he has more than 25 years of experience in Biomedical Research, and is the author of several patents and 145 articles published in international scientific journals. As a Principal Investigator, he has managed about 20 national and international research projects, and has great experience in project management and staff training. Prof. Muñoz belongs to the editorial board of several scientific journals.
He received a Ph.D. in Medicine and Surgery at the University of Córdoba and was an associate researcher at Tufts University in Boston, and at the Institut Pasteur in Paris.